(425) Relationship between hydrocodone pharmacokinetics and subjective drug effects following oral administration of an immediate-release combination of hydrocodone bitartrate and acetaminophen and MNK-155 extended-release hydrocodone bitartrate/acetaminophen (HB/APAP ER) tablets

Abstract

MNK-155 contains 7.5 mg hydrocodone bitartrate and 325 mg acetaminophen in an immediate-release (IR)/extended-release (ER) tablet formulation utilizing AcuForm™ gastroretentive drug delivery technology. MNK-155 (HB/APAP ER) is under development for the management of moderate to moderately severe acute pain with 12-hour dosing. This study evaluated the extent to which MNK-155 intact, MNK-155 crushed, and IR HB/APAP (Norco®) produce certain subjective effects that have been associated with drug abuse in recreational opioid users, such as drug liking, high, and good drug effects.